Pulse Explore Journal Club Debates Trending Researchers Journals

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Home Explore Journal Club Trending

⌘+K

The benefits of GLP-1 drugs beyond obesity | Synapse

July 18, 2024

View Full Paper

The benefits of GLP-1 drugs beyond obesity

Daniel J. DruckerUniversity of Toronto

Key Points

Key points are not available for this paper at this time.

Abstract

Glucagon-like peptide–1–based medicines have weight loss–independent actions

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

Daniel J. Drucker (Thu,) studied this question.

synapsesocial.com/papers/68e5fc83b6db643587590c84 https://doi.org/https://doi.org/10.1126/science.adn4128

Ask AI

Helpful

Bookmark

Share

View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Association of semaglutide with risk of suicidal ideation in a real-world cohort2024 · 233 citations
2Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes2023 · 2,829 citations
3Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products–induced inflammation2023 · 130 citations
4Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease2022 · 130 citations
5Glucagon-like peptide-1 receptor is involved in learning and neuroprotection2003 · 850 citations